Business profile & competitive position
AMETEK, Inc. operates in the Industrials sector, specifically the Electrical Equipment & Parts industry. It is a global manufacturer of electronic instruments and electromechanical devices, organized into two reportable segments: Electronic Instruments (EIG) and Electromechanical (EMG). EIG produces advanced analytical, test, and measurement instruments for the process, aerospace, power, and industrial markets, while EMG supplies precision motion-control solutions, medical components and devices, thermal-management systems, specialty metals, and electrical interconnects to aerospace and defense, medical, automation, and other industrial end markets.
The company’s latest financial posture shows a 19.9% net margin and a 14.7% return on equity. Those figures sit comfortably above the typical industrial-machinery average and suggest more than simple component assembly. A near-20% net margin in electrical equipment usually points to a portfolio tilted toward engineered, hard-to-replace products—analytical instruments with recurring consumables, mission-critical aerospace content, and medical-device subcomponents where qualification cycles are long. The 14.7% ROE is solid but not leveraged to an extreme, indicating that returns are being generated from profitability and asset efficiency rather than heavy balance-sheet risk. Together, the margin and ROE profile is consistent with a business that competes on specification, reliability, and customer switching costs rather than commodity pricing.
Financial posture
With a market capitalization of $54.2 billion and a trailing P/E of 33.2, AMETEK is trading at a meaningful premium to the broader Industrials universe. That valuation implies the market expects above-average growth and durable cash generation. The 19.9% net margin gives the company room to absorb input-cost pressure or modest volume softness without collapsing profitability, and the 14.7% ROE indicates capital is being deployed productively.
The beta of 0.97 tells us the stock has historically moved roughly in line with the overall market, so it is not behaving like a deeply cyclical, high-leverage industrial name. At the same time, a P/E above 30 leaves little room for operational or macro disappointment; the multiple is priced for continued execution. The current price is $236.20, sitting below the 50-day exponential moving average of $242.25, with an RSI of 45.2—neither overbought nor oversold. That technical backdrop is neutral and does not, by itself, confirm or deny the valuation story.
Strategic priorities & outlook
AMETEK’s most recent 10-K outlines a playbook built around what it calls the AMETEK Growth Model. The targets are explicit: high-single-digit annual sales growth, double-digit annual EPS growth, strong free cash flow, and a superior return on total capital. Those goals are pursued through three main levers: operational excellence, strategic acquisitions, and global expansion.
Operationally, the company emphasizes lean manufacturing, global sourcing, Design for Six Sigma, Value Engineering/Value Analysis, growth kaizens, digitalization, and artificial intelligence. Those are textbook margin-and-velocity initiatives, and they align with the 19.9% net margin the company is already producing.
Acquisition activity is the second lever. From 2021 through December 31, 2025, AMETEK completed 15 acquisitions representing approximately $1.8 billion in annualized sales. In 2025 alone, the company deployed $933.2 million in cash, net of cash acquired, to buy Kern (high-precision machining and optical inspection solutions) and FARO Technologies (3D measurement and imaging solutions). Those deals expand the precision-metrology and optical-inspection footprint and fit the stated strategy of tuck-ins in adjacent or complementary markets aligned with secular growth themes.
The third lever is geographic expansion. The company maintains best-cost manufacturing facilities in China, Czechia, Malaysia, Mexico, and Serbia, while roughly half of segment sales are international—52% of EIG net sales and 42% of EMG net sales in 2025 went to customers outside the United States. In 2025, AMETEK reported total sales of $7,401.1 million, up 6.6% from 2024, and diluted EPS of $6.40, up 7.9%. It also posted record operating income, net income, orders, and backlog.
Macro & geopolitical exposure
As an Electrical Equipment & Parts company with heavy aerospace, defense, medical, power, and industrial automation exposure, AMETEK is linked to capital-expenditure cycles, government defense budgets, commercial aerospace build rates, and healthcare capital equipment demand. Its most direct macro sensitivities are global manufacturing activity, interest rates (which influence customer capex decisions), and commodity prices for copper, specialty metals, and semiconductors used in instruments and interconnects.
Because roughly half of sales are generated outside the United States, foreign exchange is a real variable: a stronger U.S. dollar mechanically reduces the value of overseas revenue when translated back. Trade policy matters too. Tariffs on goods moving between the U.S., China, Europe, and Mexico can affect both input costs and end-market pricing. The company’s manufacturing footprint in China, Czechia, Malaysia, Mexico, and Serbia is partly a hedge against these frictions, allowing regional-for-regional production, but it still leaves the firm exposed to localization rules, export controls, and supply-chain disruptions. In aerospace and defense specifically, there is also regulatory and government-contract risk tied to certification, ITAR/EAR compliance, and budget cycles.
Recent developments
The most recent headline coverage has been relatively light on operating events and heavier on comparison and corporate housekeeping:
- On November 11, 2026, defenseworld.net published a comparison between SMC (OTCMKTS:SMCAY) and AMETEK (NYSE:AME).
- On November 9, 2026, Zacks examined AMETEK’s international revenue trends and expectations, highlighting the geographic revenue mix that investors will be watching heading into 2027.
- Also on November 9, 2026, PR Newswire reported that AMETEK promoted John Henriques and Kevin Coleman to Senior Vice Presidents, a routine but notable senior-leadership update.
- On November 6, 2026, AMETEK declared its regular quarterly dividend, continuing the shareholder-return cadence.
None of these items contain material operating announcements, but the Zacks international-revenue focus is relevant because the stock’s narrative depends partly on whether overseas demand and currency translation remain supportive.
Earnings behavior & post-earnings drift
AMETEK has an exceptionally clean recent earnings record: over the last eight reported quarters, it has beaten consensus EPS every single time, for a 100% beat rate, with an average earnings surprise of 4.3%. On the surface, that consistency looks like a recipe for steady post-earnings upside, but the price action does not fully cooperate.
The average 5-day price move following earnings across those eight quarters is -0.43%, classified as “flat.” That means beats are largely, and sometimes fully, priced in by the time the report crosses the wire. A closer look at the last four quarters illustrates the pattern:
- November 3, 2026: EPS of $2.21 beat the $2.11 estimate by 4.7%, yet the stock fell 4.62% the next day and 4.13% over the following five sessions.
- August 4, 2026: EPS of $2.09 beat the $1.99 estimate by 5.0%, with the stock rising 0.28% the next day and 0.89% over five days.
- April 30, 2026: EPS of $1.97 beat the $1.90 estimate by 3.7%, but the stock dropped 2.13% the next day and 0.33% over five days.
- February 3, 2026: EPS of $2.01 beat the $1.94 estimate by 3.6%, with the stock slipping 0.48% the next day but gaining 1.83% over five sessions.
The takeaway is that AMETEK’s strong execution is no secret. The market’s real expectation appears to be for a beat each quarter, so simply clearing consensus is not enough to trigger a sustained rally. Traders may be reacting to guidance nuances, margin trajectories, or valuation compression rather than the headline EPS beat. The next scheduled report is February 2, 2027, before the market opens, with consensus EPS at $2.28.
Frequently Asked Questions
What does AMETEK actually make, and why are its margins so high?
AMETEK makes electronic instruments and electromechanical devices across two segments: Electronic Instruments (EIG) supplies analytical, test, and measurement instruments; Electromechanical (EMG) supplies motion-control solutions, medical components, thermal-management systems, specialty metals, and electrical interconnects. Its 19.9% net margin suggests a portfolio of engineered, differentiated products where customers prioritize performance and reliability over low-cost commodity sourcing.
Why hasn’t AMETEK’s stock consistently risen after earnings beats?
AMETEK has beaten consensus EPS in all of the last eight quarters, with an average surprise of 4.3%, but the average 5-day post-earnings move is only -0.43%. The pattern indicates that beats are widely anticipated and already reflected in the stock price; the subsequent move depends more on guidance, valuation, and incremental margin commentary than on the headline beat itself.
What are the main risks AMETEK faces?
Because AMETEK competes in the Electrical Equipment & Parts industry and generates roughly half its segment sales outside the United States, key risks include global manufacturing and capex cycles, interest-rate sensitivity, currency translation, trade tariffs, and supply-chain costs for copper, specialty metals, and semiconductors. Aerospace and defense exposure adds regulatory and government-budget sensitivity.
For a deeper dive into how institutional analysts are interpreting AMETEK’s valuation, margin trajectory, and upcoming February 2027 report, readers should review the full institutional verdict and consensus breakdown on the platform.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-11-03 | $2.21 | $2.11 | +4.7% | -4.62% | -4.13% |
| 2026-08-04 | $2.09 | $1.99 | +5% | +0.28% | +0.89% |
| 2026-04-30 | $1.97 | $1.9 | +3.7% | -2.13% | -0.33% |
| 2026-02-03 | $2.01 | $1.94 | +3.6% | -0.48% | +1.83% |
| 2025-10-30 | $1.89 | $1.76 | +7.4% | - | - |
| 2025-07-31 | $1.78 | $1.69 | +5.3% | - | - |
Previous AME editions
Get the institutional verdict on AME
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the AME verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.